GlassScriptPhysician profile
Chanchal S Pant
NPI 1386319291
$1,804.59
in general payments reported to CMS, 2019-2025
22 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $454 · 2023: $578 · 2024: $375 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310 · Education: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.67 |
| Education | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $257.06 | 2022-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $191.05 | 2022-2024 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $151.60 | 2022-2024 | Vafseo, Auryxia |
| Amgen INC. | $143.27 | 2023-2025 | Tavneos, Parsabiv, Krystexxa |
| Mallinckrodt Hospital Products INC. | $142.78 | 2022-2024 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $125.94 | 2022-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $107.47 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $89.88 | 2023-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $80.91 | 2022-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $80.47 | 2022-2023 | Rayaldee |
| Ardelyx, INC. | $74.02 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $51.86 | 2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $49.70 | 2023-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $44.44 | 2022-2024 | Benlysta |
| Genzyme Corporation | $43.24 | 2022-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $37.29 | 2022 | |
| Horizon Therapeutics Plc | $29.91 | 2022 | |
| Scpharmaceuticals INC. | $28.33 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.05 | 2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $17.92 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $14.73 | 2023 | Crysvita |
| Vbi Vaccine (Delaware) INC. | $14.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chanchal Pant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.